Login Register Cart 0
Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Nanoemulsion based in-situ Gel for Ocular Delivery of Brimonidine Tartrate

Author(s): Bhupendra Prajapati*, Chetna Modi, Uma Patel and Prakash Kendre

Volume 19, Issue 3, 2024

Published on: 07 July, 2023

Page: [336 - 345] Pages: 10

DOI: 10.2174/1574885518666230626164030

Price: $65

Abstract

Background: Brimonidine tartrate is currently used to treat glaucoma; however, conventional ocular formulations have some disadvantages in terms of treating disorders like glaucoma, as less than 5% of the drug reaches a posterior segment of the eye; hence, there is a need for sustained treatment.

Objective: The objective of this study was to develop a self-nanoemulsion (SNEDDS) in-situ gel of brimonidine tartrate to investigate the sustained-release effect to improve ocular bioavailability.

Methods: Oil, surfactant, and co-surfactant were screened using the pseudo-ternary phase diagram (TPD) by aqueous-titration method based on the drug solubility. Nanoemulsions were evaluated for the pH, viscosity, % drug content, % transmittance, dispersibility, particle size, zeta-potential, TEM, and conductivity test. Nanoemulsion was incorporated into in-situ gel and evaluated for gelling capacity, pourability, gel strength, in vitro drug release study, and drug release kinetics.

Results: Castor oil (10%) as oil phase, Acrysol K-140 (10%) as surfactant, and PEG 400 (20%) as cosurfactant were selected in preparation of SNEDDS from TPD. Evaluation parameters of SNEDDS were found in an acceptable range. % Drug release showed the controlled release up to 8 hrs. Optimum % drug content and % CDR were 100.25% and 92.46% after 12hrs, respectively. Optimized SNEDDS in-situ gel followed the Higuchi model via diffusion mechanism having 0.99 R² value and exhibiting sustained release up to 12 hr. Stability study proved no significant changes during storage. In vitro, the ocular irritancy test proved suitable for ocular delivery.

Conclusion: A sustained-release formulation was obtained by developing brimonidine tartrate SNEDDS in-situ gel as a stable formulation without irritancy during ocular administration.

« Previous Next »
Graphical Abstract

[1]
Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: An overview. World J Pharmacol 2013; 2(2): 47-64.
[http://dx.doi.org/10.5497/wjp.v2.i2.47] [PMID: 25590022]
[2]
Le Bourlais C, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems-Recent advances. Prog Retin Eye Res 1998; 17(1): 33-58.
[http://dx.doi.org/10.1016/S1350-9462(97)00002-5] [PMID: 9537794]
[3]
Gote V, Sikder S, Sicotte J, Pal D. Ocular drug delivery: Present innovations and future challenges. J Pharmacol Exp Ther 2019; 370(3): 602-24.
[http://dx.doi.org/10.1124/jpet.119.256933] [PMID: 31072813]
[4]
Oh DJ, Chen JL, Vajaranant TS, Dikopf MS. Brimonidine tartrate for the treatment of glaucoma. Expert Opin Pharmacother 2019; 20(1): 115-22.
[http://dx.doi.org/10.1080/14656566.2018.1544241] [PMID: 30407890]
[5]
Yousry C, Zikry PM, Basalious EB, El-Gazayerly ON. Self-nanoemulsifying system optimization for higher terconazole solubilization and non-irritant ocular administration. Adv Pharm Bull 2020; 10(3): 389-98.
[http://dx.doi.org/10.34172/apb.2020.047] [PMID: 32665897]
[6]
Morsi N, Ibrahim M, Refai H, El Sorogy H. Nanoemulsion-based electrolyte triggered in situ gel for ocular delivery of acetazolamide. Eur J Pharm Sci 2017; 104: 302-14.
[http://dx.doi.org/10.1016/j.ejps.2017.04.013] [PMID: 28433750]
[7]
Ammar HO, Salama HA, Ghorab M, Mahmoud AA. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS PharmSciTech 2009; 10(3): 808-19.
[http://dx.doi.org/10.1208/s12249-009-9268-4] [PMID: 19536653]
[8]
Date AA, Desai N, Dixit R, Nagarsenker M. Self-nanoemulsifying drug delivery systems: Formulation insights, applications and advances. Nanomedicine (Lond) 2010; 5(10): 1595-616.
[http://dx.doi.org/10.2217/nnm.10.126] [PMID: 21143036]
[9]
Jörgensen AM, Friedl JD, Wibel R, Chamieh J, Cottet H, Bernkop-Schnürch A. Cosolvents in self-emulsifying drug delivery systems (SEDDS): Do they really solve our solubility problems? Mol Pharm 2020; 17(9): 3236-45.
[http://dx.doi.org/10.1021/acs.molpharmaceut.0c00343] [PMID: 32658482]
[10]
Prajapati BG, Patel AG, Paliwal H. Fabrication of nanoemulsion-based in situ gel using moxifloxacin hydrochloride as model drug for the treatment of conjunctivitis. Food Hydrocolloids Health 2021; 1: 100045.
[http://dx.doi.org/10.1016/j.fhfh.2021.100045]
[11]
Shafiq S, Shakeel F, Talegaonkar S, Khar RK, Ali M. Nanoemulsion as carrier for stability enhancement of ramipril. J Dispers Sci Technol 2010; 31(7): 975-9.
[http://dx.doi.org/10.1080/01932690903224144]
[12]
Vadlamudi HC, Yalavarthi PR. M v BR, Rasheed A, N T. In vitro characterization studies of self-microemulsified bosentan systems. Drug Dev Ind Pharm 2017; 43(6): 989-95.
[http://dx.doi.org/10.1080/03639045.2017.1287720] [PMID: 28121194]
[13]
Maali A, Mosavian MTH. Preparation and application of nanoemulsions in the last decade (2000-2010). J Dispers Sci Technol 2013; 34(1): 92-105.
[http://dx.doi.org/10.1080/01932691.2011.648498]
[14]
Bhalerao H, Koteshwara KB, Chandran S. Design, optimisation and evaluation of in situ gelling nanoemulsion formulations of brinzolamide. Drug Deliv Transl Res 2020; 10(2): 529-47.
[http://dx.doi.org/10.1007/s13346-019-00697-0] [PMID: 31820300]
[15]
Beg S, Sandhu PS, Batra RS, Khurana RK, Singh B. QbD-based systematic development of novel optimized solid self-nanoemulsifying drug delivery systems (SNEDDS) of lovastatin with enhanced biopharmaceutical performance. Drug Deliv 2015; 22(6): 765-84.
[http://dx.doi.org/10.3109/10717544.2014.900154] [PMID: 24673611]
[16]
Baloch J, Sohail MF, Sarwar HS, et al. Self-nanoemulsifying drug delivery system (SNEDDS) for improved oral bioavailability of chlorpromazine: In vitro and in vivo evaluation. Medicina (Kaunas) 2019; 55(5): 210-23.
[http://dx.doi.org/10.3390/medicina55050210] [PMID: 31137751]
[17]
Shiyan S, Suryani RP, Mulyani LN, Pratiwi G. Stability study of super saturable catechin-self nano emulsifying drug delivery system as antidiabetic therapy. Biointerface Res Appl Chem 2022; 12(5): 5811-20.
[18]
Parmar K, Patel J, Sheth N. Self nano-emulsifying drug delivery system for Embelin: Design, characterization and in-vitro studies. Asian J Pharmaceut Sci 2015; 10(5): 396-404.
[http://dx.doi.org/10.1016/j.ajps.2015.04.006]
[19]
Mandal S, Prabhushankar GL, Thimmasetty MKMJ, Geetha MS. Formulation and evaluation of an in situ gel-forming ophthalmic formulation of moxifloxacin hydrochloride. Int J Pharm Investig 2012; 2(2): 78-82.
[http://dx.doi.org/10.4103/2230-973X.100042] [PMID: 23119236]
[20]
Garala K, Joshi P, Patel J, Ramkishan A, Shah M. Formulation and evaluation of periodontal in situ gel. Int J Pharm Investig 2013; 3(1): 29-41.
[http://dx.doi.org/10.4103/2230-973X.108961] [PMID: 23799203]
[21]
Hosny KM, Banjar ZM. The formulation of a nasal nanoemulsion zaleplon in situ gel for the treatment of insomnia. Expert Opin Drug Deliv 2013; 10(8): 1033-41.
[http://dx.doi.org/10.1517/17425247.2013.812069] [PMID: 23795561]
[22]
Sen J, Pillai S, Gopkumar P, Sridevi G. Formulation and evaluation of muco-adhesive in-situ gel for site-specific delivery of clotrimazole. Res Rev J Pharm Nanotechnol 2014; 2(3): 1-8.
[23]
Akhani JR, Modi CD. Formulation development and evaluation of in situ gel for vaginal drug delivery of anti fungal drug. Pharma Sci Monitor 2014; 5(2): 343-64.
[24]
Rathee J, Kanwar R, Kumari L, Pawar SV, Salunke DB, Mehta SK. Preparation of α-Tocopherol based nanoemulsion for efficacious delivery of Methotrexate. J Dispers Sci Technol 2022; 44(8): 1-10.
[http://dx.doi.org/10.1080/01932691.2021.2022491]
[25]
Rocha-Filho P, Ferrari M, Maruno M, Souza O, Gumiero V. In vitro and in vivo evaluation of nanoemulsion containing vegetable extracts. Cosmetics 2017; 4(3): 32-45.
[http://dx.doi.org/10.3390/cosmetics4030032]
[26]
Pathan LS, Modi CD, Gohel MC, Udhwani NH, Thakkar VT, Rana HB. Introducing novel hybridization technique for solubility enhancement of Bosentan formulation. Food Hydrocolloids Health 2022; 2: 100055.
[http://dx.doi.org/10.1016/j.fhfh.2022.100055]
[27]
Smith R, Peters C, Inomata H. Ternary Phase Diagram. Supercritical Fluid Science and Technology. ScienceDirect 2013.
[28]
Kharwade M, Kharwade M, Subrahmanyam C, Sathesh Babu P. Cosolvency-An approach for the solubility enhancement of lornoxicam. J Pharm Res 2012; 5(8): 4204-6.
[29]
Ajazuddin Alexander A, Khichariya A, et al. Recent expansions in an emergent novel drug delivery technology: Emulgel. J Control Release 2013; 171(2): 122-32.
[http://dx.doi.org/10.1016/j.jconrel.2013.06.030] [PMID: 23831051]
[30]
Boyapally H, Nukala RK, Douroumis D. Development and release mechanism of diltiazem HCl prolonged release matrix tablets. Drug Deliv 2009; 16(2): 67-74.
[http://dx.doi.org/10.1080/10717540802586220] [PMID: 19267297]
[31]
Kajale AD, Chandewar AV. Formulation and evaluation of oral floating beads of tramodol hydrochloride. J Drug Deliv Ther 2016; 6(4): 7-16.
[http://dx.doi.org/10.22270/jddt.v6i4.1270]
[32]
Abu Shaqra QM, Al-Groom RM, Abu Shaqra AQ. Antimicrobial effectiveness in eye drops: Limited sterility versus reduction in microbial count. PDA J Pharm Sci Technol 2020; 74(3): 309-17.
[http://dx.doi.org/10.5731/pdajpst.2019.009845] [PMID: 31941794]
[33]
Elvin NC. The pH and tonicity of ophthalmic solutions. Arch Ophthalmol 1943; 29(2): 273-7.
[http://dx.doi.org/10.1001/archopht.1943.00880140119007]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy